Potential novel targets: Protease-activated receptors in idiopathic pulmonary fibrosis

Lin, Cong

Citation for published version (APA):
Chapter 2

Targeting protease activated receptor (PAR)-1 with P1pal-12 limits bleomycin-induced pulmonary fibrosis

Cong Lin1, JanWillem Duitman1, Joost Daalhuisen1, Marieke ten Brink1, Jan von der Thüsen2, Tom van der Poll1, Keren Borensztajn1,† and C. Arnold Spek1,†

1Center for Experimental and Molecular Medicine, Academic Medical Center, Amsterdam, 1105 AZ, The Netherlands.
2Department of Pathology, Medisch Centrum Haaglanden, Den Haag, 2501 CK, The Netherlands.
3Institut National de la Santé et de la Recherche Médicale (INSERM) U700, Faculté de Médecine Paris 7 Diderot, site Xavier Bichat, Paris, France
†These authors contributed equally.

ABSTRACT

Background
Idiopathic pulmonary fibrosis is the most devastating fibrotic diffuse parenchymal lung disease which remains refractory to pharmacological therapies. Therefore, novel treatments are urgently required. Protease-activated receptor (PAR)-1 is a G protein-coupled receptor that mediates critical signaling pathways in pathology and physiology. Bleomycin-induced lung fibrosis has been shown to be diminished in PAR-1 deficient mice. The purpose of this study is to investigate whether pharmacological PAR-1 inhibition is a potential therapeutic option to combat pulmonary fibrosis.

Methods
Pulmonary fibrosis was induced by intranasal instillation of bleomycin into wild-type mice with or without a specific PAR-1 antagonist (i.e. P1pal-12, a pepducin that blocks the PAR-1/G-protein interaction). Fibrosis was assessed by hydroxyproline analysis, immunohistochemistry, q-PCR and western blot for fibrotic markers expression.

Results
We first show that P1pal-12 effectively inhibits PAR-1 induced pro-fibrotic responses in fibroblasts. Next, we show that once daily treatment with 0.5, 2.5 or 10 mg/kg P1pal-12 reduced the severity and extent of fibrotic lesions in a dose-dependent manner. These findings correlated with significant decreases in fibronectin, collagen and α-SMA expression on both the mRNA and protein level in treated mice. To further establish the potential clinical applicability of PAR-1 inhibition, we analyzed fibrosis in mice treated with P1pal-12 1 or 7 days after bleomycin instillation. Interestingly, when administered 7 days after the induction of fibrosis, P1pal-12 was as effective in limiting the development of pulmonary fibrosis as when administration was started before bleomycin instillation.

Conclusions
Overall, targeting PAR-1 may be a promising treatment for pulmonary fibrosis.
INTRODUCTION

Idiopathic pulmonary fibrosis (IPF) is the most frequent diffuse fibrosing lung disease of unknown etiology.\(^1,2\) The prognosis of IPF is devastating with a 20-30% survival rate at 3-5 years after diagnosis and a mortality rate that exceeds many types of cancer. Since treatment approaches for IPF are limited, considerable effort has been made to reveal the underlying mechanisms allowing novel treatments to prolong survival.\(^2\) The molecular mechanisms underlying the pathogenesis of IPF are far from understood. However, current paradigms postulate that the development of fibrosis involves repeated epithelial cell injury leading to aberrant wound healing responses. Consistently, a hallmark of IPF is the presence of fibroblastic foci with differentiated fibroblasts which show myofibroblast phenotypes and secrete extracellular matrix (ECM) proteins that form depositions which subsequently establish fibrotic lesions.\(^1,3\)

Protease activated receptors (PARs) are seven transmembrane domain receptors that belong to the family of G-protein-coupled receptors (GPCRs).\(^4\) In contrast to other GPCRs, PAR-1 activation involves proteolytic cleavage of the receptor by serine proteases. PAR-1 was originally identified on human platelets and its best-known agonist is thrombin,\(^5\) although other ligands like FXa and certain matrix metalloproteinases have been described.\(^6,7\) Proteolytic activation of PAR-1 reveals a tethered ligand with a new N-terminus. Once irreversibly activated, PAR-1 initiates the recruitment of G\(\alpha\)-subunits, Gq, Gi and G\(_{12/13}\). Together with G\(_{\beta\gamma}\), they trigger several downstream signaling events, which contribute to a striking range of pathophysiological functions.\(^5,8-9\) In addition to proteinases, PAR-1 can be activated by synthetic agonist peptides, which are designed according to the sequence of the cleaved N-terminus.

Accumulating evidence indicates that PAR-1 induces multiple processes that may promote pulmonary fibrosis. PAR-1 modulates mitogenesis and angiogenesis, alters lung vascular permeability, stimulates fibroblasts migration, proliferation, ECM synthesis, and enhances inflammation in the pulmonary epithelium.\(^10-13\) In line, PAR-1 deficient mice are protected from bleomycin-induced acute lung inflammation and pulmonary fibrosis.\(^14\) The attenuated fibrotic response in PAR-1 deficient mice was associated with a reduction in the total collagen content in the lung and with decreased levels of proinflammatory and profibrotic mediators like interleukin (IL)-6 and monocyte chemoattractant protein-1 (MCP-1). Furthermore, PAR-1 expression is highly increased within fibroproliferative and inflammatory foci in fibrotic human lung. Overall, PAR-1 may thus have a critical contribution in promoting pulmonary fibrosis and PAR-1 may be a promising target to combat the development and progression of IPF.
In recent years, several PAR-1 antagonists have been designed; among which pepducins seem to be most promising. P1pal-12 is a cell-penetrating pepducin derived from the third intracellular loop of PAR-1. Once inserted into the plasma membrane it is delivered to the PAR-1 intracellular surface, thereby interfering with the receptor/G-proteins interaction.\(^{15}\) P1pal-12 was initially described to inhibit PAR-1-driven calcium fluxes and platelet aggregation.\(^{16,17}\) In addition, P1pal-12 has been shown to block PAR-1-mediated ERK activation \textit{in vitro}.\(^{18}\) More importantly, PAR-1 specific pepducins also showed promising \textit{in vivo} effects. Indeed, treatment with a PAR-1 specific pepducin significantly attenuated the growth of mice xenograft breast tumors,\(^{19}\) whereas the same pepducin provided remarkable inhibition of lung tumor growth in nude mice.\(^{20}\) P1pal-12 thus seems a promising PAR-1 inhibitor for preclinical experiments.

Here, we hypothesized that targeting PAR-1 with P1pal-12 may limit the development and progression of pulmonary fibrosis and tested this hypothesis using a well-established murine model of bleomycin-induced pulmonary fibrosis.

**MATERIALS AND METHODS**

**Cells and reagents**

Mouse embryonic NIH3T3 fibroblasts (ATCC, Manassas, VA; CRL-1658) were cultured in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10% fetal calf serum (FCS). Cells were grown at 37°C in an atmosphere of 5% CO\(_2\). Unless indicated otherwise, cells were washed twice with PBS and serum-starved for 4 hours before stimulation. Thrombin was from Sigma (St-Louis, MO), whereas PAR-1 agonist peptide (PAR-1-AP; H-SFLLRN-NH\(_2\)) and P1pal-12 (palmitate-RCLSSSAVANRS-NH\(_2\)) were from GL Biochem Ltd (Shanghai, China).

**Western Blot**

Western blots were performed essentially as described before.\(^{21}\) For details, see the supplementary method section.

**Wound Scratch assay**

Scratch assays were performed essentially as described before.\(^{21}\) For details, see the supplementary method section.
Animal Model of Pulmonary Fibrosis
Ten-week-old wild-type C57Bl/6 mice were purchased from Charles River (Someren, Netherlands). All procedures were performed in accordance with the Institutional Standards for Humane Care and Use of Laboratory Animals. Experiments were approved by the Animal Care and Use Committee of the Academic Medical Center Amsterdam.

Bleomycin (Sigma, St-Louis) was administered intranasally (1 mg/kg) under anesthesia. In the dose finding experiment, animals were instilled with 0.5, 2.5 or 10 mg/kg P1pal-12 30 minutes before bleomycin administration and subsequently once daily until the end of the experiment. In the delayed treatment experiment, mice were treated once daily with 2.5 mg/kg P1pal-12 starting one or seven-days after bleomycin instillation. In both experiments, 6% DMSO in saline was administered as solvent control. Mice were sacrificed 14 days after bleomycin instillation, after which one lung was taken for histology and one was homogenized.

Cytokine/Chemokine Assays
TGF-β1 was measured with the Mouse TGF-beta 1 DuoSet kit (R&D systems, UK). IL-6 and MCP-1 were measured using the BD Cytometric Bead Array Mouse Inflammation Kit (BD, NJ, USA) following the manufacturer’s instructions. Detection limits were 2.5 pg/ml for IL-6 and 20 pg/ml for MCP-1.

Hydroxyproline Assay
Right lungs were homogenized after which samples were processed for hydroxyproline content analysis using the hydroxyproline assay kit (Sigma, Netherlands) as per the manufacturer’s instructions. For details, see the supplementary method section.

(Immunohisto)Histological Analysis
Histological examination and Ashcroft score were performed as described before.22 Smooth muscle actin (α-SMA) staining was graded in a blinded fashion on a scale from 0 to 3 as described before.23 Pictures of collagen staining were taken to cover the entirety of all sections. Color intensity of stained areas was analyzed semi-quantitatively with ImageJ and expressed as percentage of the surface area essentially as described before.24,25 For details, see the supplementary method section.

Quantitative PCR
mRNA expression levels were quantified by real-time PCR as indicated in the supplementary method section.
Statistics
Statistical analyses were conducted using GraphPad Prism (GraphPad software, San Diego). Comparisons between conditions were analyzed using two tailed unpaired t-tests for normally distributed data, otherwise Mann-Whitney analysis was performed. P<0.05 was considered significant.

RESULTS

P1pal-12 inhibits PAR-1-mediated signaling pathways in fibroblasts
Several studies have shown that PAR-1 activation leads, among others, to extracellular regulated kinase (ERK) phosphorylation, which is an important signaling pathway regulating fibroblast proliferation and migration.26 Pepducins have been shown to efficiently inhibit PAR-1-driven ERK phosphorylation in cancer cells.20 Importantly however, pepducins may act in a cell type dependent manner.27 Therefore, we assessed whether P1pal-12 also inhibits PAR-1-driven ERK activation in fibroblasts. As shown in Figure 1A, treatment of fibroblasts with 100 μM PAR-1-AP resulted in ERK1/2 phosphorylation. This PAR-1-AP-induced ERK phosphorylation was completely inhibited in 10 μM P1pal-12-pretreated cells. P1pal-12 thus effectively antagonizes PAR-1-mediated signaling in murine fibroblasts.

P1pal-12 inhibits PAR-1-dependent fibroblast differentiation, proliferation and migration
PAR-1 activation on fibroblasts has been demonstrated to induce several profibrotic processes like fibroblast migration, proliferation and differentiation.6,28 Consequently, we assessed whether P1pal-12 also antagonizes these PAR-1-driven fibroproliferative responses. As shown in Figure 1B, both PAR-1-AP (100 μM) and thrombin (1 U/ml) induced fibroblast differentiation and ECM synthesis as evident from increased α-SMA (hallmark of fibroblast differentiation) and collagen expression. This increased α-SMA and collagen expression was clearly down-regulated by the treatment with 10 μM P1pal-12. Importantly, TGFβ-induced collagen production is independent from P1pal-12 treatment (Supplementary Figure 1). Furthermore, we observed that PAR-1 stimulation induced fibroblast migration/proliferation in wound scratch assays, as evident from significantly smaller wound sizes (70-80%). Again, P1pal-12 treatment inhibited PAR-1-AP-induced wound closure (Figure 1C-D). Overall these in vitro experiments show that P1pal-12 effectively blocks PAR-1-induced profibrotic effects of fibroblasts.
Targeting PAR-1 in pulmonary fibrosis

Figure 1. P1pal-12 inhibits PAR-1 induced pro-fibrotic responses in fibroblasts. (A) Western blot analysis of ERK phosphorylation in NIH3T3 cells after stimulation with 100 μM PAR-1-AP in the absence or presence of P1pal-12 (10 μM). P1pal-12 was added 30 minutes before PAR-1-AP stimulation. Total ERK served as loading control. (B) Western blot analysis of α-SMA and collagen expression in NIH3T3 cells 24 hours after stimulation with thrombin (1 U/ml) or 100 μM PAR-1-AP in the absence or presence of P1pal-12 (10 μM). P1pal-12 was added 30 minutes before thrombin or PAR-1-AP stimulation. β-actin served as a loading control. (C) Wound size of NIH3T3 fibroblast monolayers after treatment with either DMSO (control) or PAR-1-AP (100 μM) for 18 hours in the presence or absence of P1pal-12. Cells were pre-incubated with 10 μM P1pal-12 for 30 min as indicated. Shown are photographs of representative microscopic fields. (D) Quantification of the results depicted in (C) as described in the Materials and Methods section. Data are expressed as mean±SEM (n=6). *** P<0.001.
P1pal-12 dose-dependently limits the development of pulmonary fibrosis in a murine bleomycin model

We next examined whether P1pal-12 limits fibrosis in a murine model of bleomycin-induced pulmonary fibrosis. To this end, mice were intranasally instilled with different concentrations of P1pal-12, after which the extent and severity of fibrosis was determined. As shown in Figure 2A-B, bleomycin instillation induced extensive patchy fibrotic foci accompanied by a marked accumulation of inflammatory cells and increased deposition of ECM. Low dose P1pal-12 treatment (0.5 mg/kg, Figure 2C) marginally reduced bleomycin-induced fibrosis (about 10%) whereas intermediate (2.5 mg/kg) and high (10 mg/kg) P1pal-12 doses significantly reduced the severity of regional interstitial fibrosis (approximately 25% and 20%) and diminished the destruction of alveolar units (compare figures 2D-E with 2B). Quantification of the bleomycin-induced histological changes using the Ashcroft score shows that P1pal-12 treatment results in less severe fibrotic lesions (Figure 2F).

It is well recognized that accumulation of α-SMA and ECM proteins (like collagen and fibronectin) can lead to organ-destructive remodeling, which also occur in fibrotic foci and are considered as hallmarks of IPF. To substantiate that P1pal-12 limits experimental fibrosis, we next analyzed α-SMA expression immunohistochemically. Dramatic α-SMA expression was seen in focal fibrotic lesions after bleomycin instillation (compare Figure 2G and H). Low dose P1pal-12 treatment did marginally reduce α-SMA expression, whereas intermediate P1pal-12 doses significantly reduced (about 40%) α-SMA levels (Figure 2I-J). Noteworthy, although the 10 mg/kg P1pal-12 dose also strongly reduced α-SMA levels; it did not reach statistical significance (Figure 2K-L).

To confirm the inhibitory effect of P1pal-12 on bleomycin-induced fibrosis, we analyzed collagen accumulation in the lung. Collagen levels in lung homogenates largely increased after bleomycin instillation. As shown in Figure 3A-B, 2.5 and 10 mg/kg P1pal-12 administration considerably reduced collagen deposition in the lungs. In contrast, mice treated with 0.5 mg/kg P1pal-12 showed similar collagen deposition as mice not treated with P1pal-12. In line, Masson-trichrome and collagen stainings showed high collagen levels in bleomycin instilled mice, which were significantly reduced in mice treated with 2.5 or 10 mg/kg P1pal-12 (Figure 3C-D). Finally, we confirmed these observations by analyzing hydroxyproline content in right lung homogenates. As shown in Figure 3E, collagen level (calculated according to the hydroxyproline content) increased almost 3 fold in bleomycin treated mice compared with solvent controls. Importantly, collagen
Figure 2. P1pal-12 treatment affords protection against bleomycin-induced pulmonary fibrosis. (A-E, ×100) Representative H&E stained lung tissue sections obtained 14 days after saline (A) or bleomycin instillation in mice treated with 0 mg/kg (B), 0.5 mg/kg (C), 2.5 mg/kg (D), or 10 mg/kg P1pal-12 (E). (F) Quantification of pulmonary fibrosis using the Ashcroft score in control mice and mice treated with P1pal-12. Data are expressed as mean±SEM (n=8 per group). (G-K, ×100) Representative pictures of α-SMA deposition in lung tissue sections obtained 14 days after saline (G) or bleomycin instillation of untreated (H) mice and mice treated with 0.5 mg/kg (I), 2.5 mg/kg (J) or 10 mg/kg (K) P1pal-12. (L) Quantification of α-SMA deposition as depicted in panels G-K. Data are expressed as mean±SEM (n=8 per group). * P<0.05. Dashed lines in the quantification figure represent solvent-treated controls.
levels decreased 24.9±7.8%, 36.4±4.5% and 29.7±3.5% after treatment with 0.5, 2.5 and 10 mg/kg P1pal-12 respectively.

Next, we analyzed mRNA expression levels of \( \alpha \)-SMA, collagen and fibronectin in the lungs. All these genes were highly expressed in response to bleomycin treatment and high as well as intermediate doses of P1pal-12 treatment strongly reduced their expression (Figure 4A-C). Low dose P1pal-12 treatment did not inhibit bleomycin-induced profibrotic gene expression.
Finally, we assessed TGF-β1 levels in lung homogenates as TGF-β1 is one of the most typical profibrotic mediators and is frequently over-expressed in fibrotic diseases. TGF-β1 levels increased in bleomycin-instilled untreated mice (two-fold increase, Figure 4D) compared with saline treated mice. The 2.5 mg/kg dose of P1pal-12 attenuated the TGF-β1 increase by about 50%. IL-6 and MCP-1 levels were also increased in bleomycin-instilled mice and again treatment with 2.5 mg/kg P1pal-12 significantly attenuated these increases by 65±3% and 36±3% respectively. Treatment with 10 mg/kg P1pal-12 also led to a decrease in these cytokine levels, although it failed to reach statistical significance (Figure 4E-F).

Overall, P1pal-12 limits bleomycin-induced pulmonary fibrosis, and the most significant effects were reached at the dose of 2.5 mg/kg. Therefore, we selected this intermediate dose for our subsequent studies.

Figure 4. P1pal-12 treatment reduces bleomycin-induced pro-fibrotic gene expression and cytokine increases. Expression of α-SMA (A), collagen (B) and fibronectin (C) mRNA levels in lung homogenates obtained 14 days after saline or bleomycin instillation in mice treated with 0-10mg/kg P1pal-12 was assessed by real-time RT-PCR. Data are expressed relative to the amount of input RNA. TGF-β1 (D), IL-6 (E) and MCP-1 (F) levels in lung homogenates obtained 14 days after saline or bleomycin instillation in mice treated with 0-10 mg/kg P1pal-12. Data are expressed as mean±SEM (n=8 per group). * P<0.05, ** P<0.01. Dashed lines represent solvent-treated controls.
Delayed treatment with P1pal-12 effectively limits pulmonary fibrosis progression in a murine bleomycin model of pulmonary fibrosis

After having established that long-term treatment with P1pal-12 effectively limits pulmonary fibrosis, we next investigated whether delayed treatment starting after the initiation of fibrosis would still limit pulmonary fibrosis. Daily P1pal-12 (2.5mg/kg) administration was started either 1 (inflammatory phase) or 7 (fibrotic phase) days after bleomycin instillation. As shown in Figure 5A-C, lungs from mice not treated with P1pal-12 again showed severe fibrotic lesions induced by bleomycin treatment (more than fourfold increase compared with saline control). Interestingly, delayed P1pal-12 treatment reduced bleomycin-induced lung damage as evident from lower Ashcroft scores. However, scores of the one-day delayed-treatment group did not reach

Figure 5. Delayed P1pal-12 treatment effectively attenuates bleomycin-induced pulmonary fibrosis. (A-C) Representative H&E stained lung tissue sections obtained 14 days after bleomycin instillation in untreated mice (A) and mice treated with 2.5 mg/kg P1pal-12 from day 1 (B) or day 7 (C) after bleomycin instillation. (D) Quantification of pulmonary fibrosis using the Ashcroft score in untreated mice and mice treated with P1pal-12. Data are expressed as mean±SEM (n=8 per group). (E-G) Representative pictures of α-SMA deposition in lung tissue sections obtained 14 days after bleomycin instillation of untreated (E) mice and mice treated with 2.5 mg/kg P1pal-12 from day 1 (F) or day 7 (G) after bleomycin instillation. (H) Quantification of α-SMA deposition as depicted in panels E-G. Data are expressed as mean±SEM (n=8 per group). * P<0.05. Dashed line in the quantification figure represents solvent-treated controls.
Figure 6. Delayed P1pal-12 treatment attenuates bleomycin-induced collagen deposition and reduces gene expression of fibrotic markers. (A) Western blot analysis of collagen expression in lung homogenates obtained 14 days after bleomycin instillation in untreated mice and mice treated with 2.5 mg/kg P1pal-12 from day 1 or day 7 after bleomycin instillation. GAPDH served as a loading control. Shown are three representative samples per condition from a group of 8. (B) Quantification of the results depicted in (A). (C) Representative pictures of Masson-trichrome (×100) and collagen stained lung tissue sections (×200) obtained 14 days after bleomycin instillation in untreated mice and mice treated with 2.5 mg/kg P1pal-12 from day 1 or day 7 after bleomycin instillation. (D) Quantification of collagen immunostaining (semi-quantitative image analysis). (E) Collagen content in lung homogenates obtained 14 days after saline or bleomycin instillation in mice treated with different doses of P1pal-12. Expression of α-SMA (F), collagen (G) and fibronectin (H) mRNA levels in lung homogenates obtained 14 days after bleomycin instillation in untreated mice and mice treated with 2.5 mg/kg P1pal-12 from day 1 or day 7 post-bleomycin instillation as assessed by real-time RT-PCR. Data are expressed relative to the amount of input RNA. Data are expressed as mean±SEM (n=8 per group; * P<0.05, ** P<0.01, *** P<0.001). Dashed lines in the quantification figures represent solvent-treated controls.
statistical significance (Figure 5D). Consistently, α-SMA expression levels were increased in bleomycin instilled lungs and these levels were significantly reduced in the 1- and 7-day delayed treatment groups by 27±3.8% and 32±8.0% respectively (Figure 5E-H).

Next, we determined pulmonary collagen levels and both 1- and 7-days delayed P1pal-12 treatment clearly reduced the expression of collagen (Figure 6A-B). However, again, the effect of 1-day delayed treatment did not reach statistical significance. The decrease in collagen deposition by delayed P1pal-12 treatment was confirmed using collagen immunohistochemistry analysis and Masson-trichrome staining (Figure 6C-D). In line, collagen content of bleomycin instilled lungs increased by more than 4 fold compared to saline control and this increase was attenuated by 34.5±3.8% and 40.7±3.7% in the 1- and 7-day delayed treatment groups (Figure 6E). Moreover, the decreases of α-SMA and collagen expression after delayed-treatment were confirmed on the mRNA level (Figure 6F-H), whereas fibronectin mRNA levels were also reduced after delayed treatment as compared to P1pal-12 untreated controls (Figure 6H).

Overall, delayed treatment with P1pal-12 effectively limits the progression of bleomycin-induced pulmonary fibrosis. It is noteworthy however, that P1pal-12 treatment starting 7 days after bleomycin instillation seems to be more effective compared to one-day delayed-treatment.

**DISCUSSION**

IPF is the end result of a heterogeneous group of disorders with a devastating prognosis and very few therapeutic options.1 Interestingly, PAR-1 has been proven to play an important role in mediating pro-inflammatory and pro-fibrotic effects in vitro, and preclinical experimental animal data showed that PAR-1 drives the progression of pulmonary fibrosis as mice that lack PAR-1 were protected against bleomycin-induced pulmonary fibrosis.14 In this study, we assessed whether treatment with a PAR-1 inhibitor limits experimental pulmonary fibrosis, and we show that pharmacological inhibition of PAR-1 with P1pal-12 indeed effectively limits pulmonary fibrosis in the murine bleomycin model. More specifically, we first show that P1pal-12 effectively blocks PAR-1 pro-fibrotic effects in fibroblasts. Pre-incubation with P1pal-12 before PAR-1-AP or thrombin stimulation blocked ERK activation, diminished α-SMA expression and reduced proliferation/migration. Importantly, we were able to confirm these data in in vivo experiments by showing that bleomycin-induced fibrosis was significantly
Targeting PAR-1 in pulmonary fibrosis

attenuated in mice treated with both 2.5 and 10 mg/kg P1pal-12 administered once daily. Both histological hallmarks of fibrosis and pro-fibrotic protein and gene expression were significantly reduced after P1pal-12 treatment. Interestingly, finally we show that P1pal-12 still effectively limits pulmonary fibrosis when administration started 7 days after the induction of fibrosis by bleomycin instillation.

Interestingly, the observed effects of P1pal-12 are comparable to those observed in PAR-1 deficient animals, which confirms the efficacy of P1pal-12. In both PAR-1 deficient mice and P1pal-12 treated mice, the severity of the fibrotic lesions was reduced by around 1 point in the Ashcroft score as compared to untreated control mice. Moreover, collagen accumulation in the lung was reduced by around 55% in PAR-1 deficient mice, whereas P1pal-12 treatment reduced collagen deposition by approximately 40%. Finally, MCP-1 and TGF-β1 levels were increased in response to bleomycin instillation and these increases were diminished by 35% and 50% in PAR-1 deficient mice and by 36% and 50% in P1pal-12 treated animals for MCP-1 and TGF-β1 respectively. Overall, P1pal-12 treatment thus efficiently blocks PAR-1 driven pulmonary fibrosis.

Obviously, the fact that P1pal12 limits pulmonary fibrosis as efficiently as PAR-1 deficiency is scientifically interesting. However, more clinically relevant is the observation that when P1pal-12 treatment was started 7 days after the induction of fibrosis, it still significantly reduced fibrosis. The reductions in Ashcroft score, collagen deposition and profibrotic gene expression were similar to those observed in mice in which treatment was started before the induction of fibrosis. Inhibition of PAR-1 may thus be a promising therapeutic strategy for treating fibrosis, although future clinical studies are required to confirm this notion.

Two interesting findings of our study are that 2.5 mg/kg P1pal-12 seemed more effective in reducing fibrosis than the 10 mg/kg dose, and that initiation of treatment 7 days after bleomycin instillation was more effective than when treatment was started one day after the induction of fibrosis. Although we do not have a conclusive explanation for these surprising findings, it is tempting to speculate that the different dose- and time-dependent effects are related to the dual role of PAR-1 in inflammation and fibrosis. In pulmonary fibrosis, PAR-1 is mainly considered to trigger inflammatory responses; however recent data suggest that PAR-1 also exerts anti-inflammatory functions. Therefore, the extent and/or timing of PAR-1 inhibition may influence the balance of its anti-inflammatory and pro-inflammatory properties. Alternatively, the slight differ-
ences observed may merely reflect the variability/inaccuracy associated with the analysis rather than any definable biological phenomenon.

When interpreting our data, several issues should be taken into consideration. First, although the bleomycin model is the best available model to study pulmonary fibrosis, it does not completely mimic the progression of fibrosis in IPF patients. For example, the spontaneous resolution of fibrosis in this model fails to represent the irreversibility seen in IPF patients. In addition, fibrosis develops fast in the bleomycin model, whereas it actually takes years to progress in patients. Second, we expressed our mRNA data as relative to the amount of input RNA as opposed to the more frequently used normalization of gene expression against housekeeping genes. We opted for this approach because it is well-known that expression of commonly used housekeeping genes is highly dependent on the experimental conditions and the use of total cellular RNA has been proposed as the best alternative for data normalization. In agreement, we analyzed several different “housekeeping genes” (Supplementary Figure 2 for glyceraldehyde-3-phosphate dehydrogenase (GAPDH), Hypoxanthine–Guanine Phosphoribosyltransferase (HPRT) and 18S rRNA) and observed considerable variability between the different “house-keeping” genes. Importantly however, mRNA levels as expressed relative to the amount of input RNA do correspond with the histological scores and hydroxyproline analysis. Finally, we did observe a significant difference in IL-6 levels between untreated mice and mice receiving 2.5 mg/kg once daily. Such a difference in IL-6 was not shown in PAR-1 deficient animals. Most likely this is explained by the different time point at which IL-6 was measured (6 and 14 days after bleomycin instillation for PAR-1 deficient and P1pal-12 treated mice respectively), although we cannot exclude small differences due to genetic PAR-1 deficiency versus pharmacological PAR-1 inhibition.

In conclusion, P1pal-12 significantly blocks PAR-1-induced pro-fibrotic effects in vitro and inhibits bleomycin-induced pulmonary fibrosis in mice. Thus, targeting PAR-1 may be clinically relevant and may meet the urgent medical need for treating patients with pulmonary fibrosis.
REFERENCES


Supplementary figures

Supplementary figure 1. TGFβ induces collagen production is independent from P1pal-12 treatment. Western blot analysis of collagen expression by NIH3T3 cells stimulated with TGFβ in the presence and absence of P1pal-12. Tubulin was used as loading control.

Supplementary figure 2. Expression of GAPDH, HPRT and 18S rRNA mRNA levels in lung homogenates obtained 14 days after bleomycin instillation in untreated mice and mice treated with 2.5 mg/kg P1pal-12 from day 1 or day 7 post-bleomycin instillation as assessed by real-time RT-PCR.

Supplementary methods

Western Blot In brief, cells or lung homogenates were lysed in Laemmli lysis buffer and the lysates were incubated for 5 minutes at 95°C. Afterwards, protein samples were separated by 10% SDS gel electrophoresis and transferred to a PVDF membrane (Millipore, Billerica, MA). Membranes were blocked for 1 hour in 4% milk in TBST and incubated overnight with monoclonal antibodies against α-smooth muscle actin (α-SMA), β-actin, GAPDH, collagen (all Santa Cruz, CA), phospho-ERK1/2 or total ERK1/2 (both Cell Signaling, Leiden) at 4°C. All secondary antibodies were horseradish peroxidase (HRP)-conjugated from DakoCytomation (Glostrup, Denmark) and diluted according to the manufacturer’s instructions. Blots were imaged using Lumilight plus ECL substrate from Roche (Almere, The Netherlands) on an ImageQuant LAS 4000 biomolecular imager from GE Healthcare (Buckinghamshire, U.K). For quantification, densitometry was performed...
with ImageJ (NIH, Maryland, U.S) using the histogram function in a selected area of mean gray value for each band. Values for the protein of interest were corrected for those of β-actin or GAPDH.

**Wound scratch assays** Cells were seeded in six-well plates in DMEM supplemented with 10% FCS. After the cells formed a confluent monolayer, a scratch was created in the center of the monolayer by a sterile p200 pipette tip. Next, medium was removed and cells were washed with serum-free medium to remove floating debris. The cells were subsequently incubated for 18 hours with serum-free medium (negative control), serum-free medium supplemented with 100 μM PAR-1-AP, or serum-free medium containing 100 μM PAR-1-AP and 10 μM P1pal-12. When indicated, cells were pre-incubated with 10 μM P1pal-12 for 30 minutes before scratching. The ability of cells to close the wound was assessed by comparing the 0- and 18-hour phase-contrast micrographs of 6 marked points along the wounded area. The percentage of non-recovered wound area was calculated by dividing the non-recovered area after 18 hours by the initial area at 0 hour as previously described.

**Hydroxyproline Assay** Right lungs were homogenized in saline (100 mg lung in 900 μl saline) and stored at -20°C. Next, hydroxyproline content was analysed using the hydroxyproline assay kit (Sigma, Netherlands) as per the manufacturer’s instructions. In detail, 40 μl homogenate was added to 60 μl water after which 100 μl 12N HCL was added, Samples were hydrolyzed at 120°C for 3 hours after which 20 μL of the hydrolyzed samples were transferred to a 96 well plate. Subsequently, the plate (also containing a hydroxyproline standard curve) was incubated at 60°C till all fluid was evaporated (approximately 2 hours) after which the chloramine T/Oxidation buffer mixture was added. After 5 minute incubation on a shaker at room temperature, 100 μL of the Diluted DMAB Reagent was added and the samples were incubated for 90 minutes at 60 °C. Finally, the absorbance was measured at 560 nm and hydroproline content was calculated according to the standard curve. Right lung collagen content was calculated by multiplying the hydroxyproline values with a factor 7.4 (because collagen contains on average 13.5% hydroxyproline). Finally, right lung collagen levels were multiplied by a factor 2 to obtain total lung collagen content.

**Histological Analysis** Briefly, the excised lung was fixed in formalin, embedded in paraffin and 4-μm-thick slides were subsequently deparaffinized, rehydrated and washed in deionized water. Slides were stained with hematoxylin and eosin (H&E) and Masson's
trichrome according to routine procedures. In H&E staining, severity of fibrosis was assessed according to the Ashcroft scoring system using a 200× magnification. Two independent observers were blinded to the treatment group and an average of 10 fields of each lung section were selected and scored. The average Ashcroft score was calculated by averaging the individual field scores.

**Immunohistochemistry** Four-μm sections were first deparaffinized and rehydrated. Endogenous peroxidase activity was quenched with 0.3% H₂O₂ in methanol. Smooth muscle actin (α-SMA) and collagen staining were performed with an anti-α-smooth muscle actin antibody (1:1000, 24 hour at 4°C, Santa Cruz, CA) or anti-collagen-I antibodies (1:800, overnight at 4°C, GeneTex, CA). A horseradish peroxidase-conjugated polymer detection system (ImmunoLogic, Duiven, the Netherlands) was applied for visualization, using an appropriate secondary antibody and diaminobenzidine (DAB) staining. Slides were photographed with a microscope equipped with a digital camera (Leica CTR500).

**qPCR** Total RNA was isolated from lung homogenates with TriPure (Roche, Almere, Netherlands) following the manufacturer’s recommendations. q-PCR was performed with SYBR Green PCR master Kit (Roche) using the following primers: α-SMA: forward 5’-TCCCTGGAGAAGAGCTACGAACT-3’ and reverse 5’-GATGCCCGCTGACTCCAT-3’; collagen 1A1: forward 5’-ACCTAAGGGTACCGCTGGA-3’ and reverse 5’-TCCAGCTTCTCCATCTTTGC-3’; Fibronectin forward 5’-CCATGATAGGAGAACAGTGGCA-3’ and reverse 5’-GAAGCACTCAATGGGGCA-3’. The results were calculated as Efficiency-Cp.

**Reference**